Cargando…

HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy

The recent approval of clincially effective immune checkpoint inhibitors illustrates the potential of cancer immunotherapy. A challenging task remains the identification of specific targets guiding immunotherapy. Facilitated by technical advances, the direct identification of physiologically relevan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peper, Janet Kerstin, Bösmüller, Hans-Christian, Schuster, Heiko, Gückel, Brigitte, Hörzer, Helen, Roehle, Kevin, Schäfer, Richard, Wagner, Philipp, Rammensee, Hans-Georg, Stevanović, Stefan, Fend, Falko, Staebler, Annette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910750/ https://www.ncbi.nlm.nih.gov/pubmed/27467910 http://dx.doi.org/10.1080/2162402X.2015.1065369

Ejemplares similares

HLA ligandome tumor antigen discovery for personalized vaccine approach
por: Rammensee, Hans-Georg, et al.
Publicado: (2013)

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
por: Reustle, Anna, et al.
Publicado: (2020)

Pitfalls in HLA Ligandomics—How to Catch a Li(e)gand
por: Fritsche, Jens, et al.
Publicado: (2021)

Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome*
por: Mylonas, Roman, et al.
Publicado: (2018)

The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination
por: Mühlenbruch, Lena, et al.
Publicado: (2023)

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
por: Nelde, Annika, et al.
Publicado: (2016)

The immunopeptidomic landscape of ovarian carcinomas
por: Schuster, Heiko, et al.
Publicado: (2017)

The pulmonary pathology of COVID-19
por: Bösmüller, Hans, et al.
Publicado: (2021)

Pre-fractionation Extends but also Creates a Bias in the Detectable HLA Class Ι Ligandome
por: Demmers, Laura C., et al.
Publicado: (2019)

The HLA Ligandome Comprises a Limited Repertoire of O-GlcNAcylated Antigens Preferentially Associated With HLA-B*07:02
por: Mukherjee, Soumya, et al.
Publicado: (2021)

Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity
por: Mommen, Geert P. M., et al.
Publicado: (2016)

What Is the Role of HLA-I on Cancer Derived Extracellular Vesicles? Defining the Challenges in Characterisation and Potential Uses of This Ligandome
por: Boyne, Caitlin, et al.
Publicado: (2021)

Targeting the MHC Ligandome by Use of TCR-Like Antibodies
por: Høydahl, Lene Støkken, et al.
Publicado: (2019)

Tumour‐associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles
por: Kumar, Pankaj, et al.
Publicado: (2022)

High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome
por: Chong, Chloe, et al.
Publicado: (2018)

Ligandomes obtained from different HLA-class II-molecules are homologous for N- and C-terminal residues outside the peptide-binding cleft
por: Kampstra, Arieke S.B., et al.
Publicado: (2019)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

‘Hotspots’ of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization
por: Müller, Markus, et al.
Publicado: (2017)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors
por: Tien Anh, Duong, et al.
Publicado: (2023)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation
por: Stickel, Juliane S, et al.
Publicado: (2011)

The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation
por: Bösmüller, Hans, et al.
Publicado: (2020)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Biobanking in times of crisis – The COVID-19 Autopsy and Biosample Registry Baden-Wuerttemberg
por: Domke, Lisa M., et al.
Publicado: (2022)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma
por: Lengerke, Claudia, et al.
Publicado: (2011)

Histone deacetylase 10 structure and molecular function as a polyamine deacetylase
por: Hai, Yang, et al.
Publicado: (2017)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylases in RA: epigenetics and epiphenomena
por: Grabiec, Aleksander M, et al.
Publicado: (2010)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Targeting histone deacetylases for the treatment of disease
por: Lawless, M W, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_tj4q7qkmb1k9lsi1o96sk9hvsm